Evidence map›Paper›PMID 14678336›Full record

ReviewBritish journal of clinical pharmacology2004

Stroke, dementia, and drug delivery.

G A Ford, C A Bryant, A A Mangoni, S H D Jackson

Abstract readReview
In one paragraph

Review in British journal of clinical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Neuroprotection in experimental stroke with targeted neurotrophins.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2005
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

G A FordDepartment of Health Care of the Elderly, Guy's, King's, and St Thomas' School of Medicine, King's College London, London, UK. g.a.ford@newcastle.ac.uk
C A Bryant
A A Mangoni
S H D Jackson

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke and dementia represent a major health burden for elderly subjects as they are associated with significant morbidity and mortality. The rates of stroke and dementia are progressively increasing due to the ageing population in most westernized countries. Therefore, both these conditions represent a major therapeutic target. However, the therapeutic options available for the management of stroke and dementia remain largely unsatisfactory, the main reason being the difficulty in transferring the results obtained in animal and in vitro studies to the clinical setting. This review focuses on the recent advances in pathophysiology and treatment of these conditions and future directions for research. Moreover, the technique of functional magnetic resonance imaging is discussed in detail as a tool to assess the effects of therapeutic agents on the central nervous system and monitor the progression of diseases. Finally, an overview of the issue of drug delivery into the central nervous system is presented.

Indexed as

Anticholesteremic AgentsAnticoagulantsAspirinClinical Trials as TopicDementiaFibrinolytic AgentsHumansHypertensionMagnetic Resonance ImagingNeuroprotective AgentsPlatelet Aggregation InhibitorsStrokeTomography, X-Ray ComputedAnticholesteremic AgentsAnticoagulantsAspirinFibrinolytic AgentsNeuroprotective AgentsPlatelet Aggregation Inhibitors

Identifiers

PMID14678336
PMCPMC1884409

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.